206 related articles for article (PubMed ID: 15466181)
21. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.
Grisham RN; Iyer G; Garg K; Delair D; Hyman DM; Zhou Q; Iasonos A; Berger MF; Dao F; Spriggs DR; Levine DA; Aghajanian C; Solit DB
Cancer; 2013 Feb; 119(3):548-554. PubMed ID: 22930283
[TBL] [Abstract][Full Text] [Related]
22. Ovarian high-grade serous carcinoma with a noninvasive growth pattern simulating a serous borderline tumor.
Imamura H; Ohishi Y; Aman M; Shida K; Shinozaki T; Yasutake N; Sonoda K; Kato K; Oda Y
Hum Pathol; 2015 Oct; 46(10):1455-63. PubMed ID: 26232113
[TBL] [Abstract][Full Text] [Related]
23. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
24. v-Raf murine sarcoma viral oncogene mutation status in serous borderline ovarian tumors and the effect on clinical behavior.
Verbruggen MB; Sieben NL; Roemen GM; Rockx DA; van Diest PJ; Verheijen RH; Dorsman JC
Int J Gynecol Cancer; 2009 Dec; 19(9):1560-3. PubMed ID: 19955937
[TBL] [Abstract][Full Text] [Related]
25. High Frequency of
Ishibashi T; Nakayama K; Razia S; Ishikawa M; Nakamura K; Yamashita H; Dey P; Iida K; Kurioka H; Nakayama S; Otsuki Y; Ishikawa N; Kyo S
Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31892193
[TBL] [Abstract][Full Text] [Related]
26. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
28. KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
Nakamura K; Nakayama K; Ishibashi T; Ishikawa N; Ishikawa M; Katagiri H; Minamoto T; Sato E; Sanuki K; Yamashita H; Iida K; Sultana R; Kyo S
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128903
[TBL] [Abstract][Full Text] [Related]
29. Molecular pathology of epithelial ovarian cancer.
Christie M; Oehler MK
J Br Menopause Soc; 2006 Jun; 12(2):57-63. PubMed ID: 16776856
[TBL] [Abstract][Full Text] [Related]
30. Both BRAF and KRAS mutations are rare in colorectal carcinomas from patients with hereditary nonpolyposis colorectal cancer.
Miyaki M; Iijima T; Yamaguchi T; Kadofuku T; Funata N; Mori T
Cancer Lett; 2004 Jul; 211(1):105-9. PubMed ID: 15194222
[TBL] [Abstract][Full Text] [Related]
31. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.
Nakayama N; Nakayama K; Yeasmin S; Ishibashi M; Katagiri A; Iida K; Fukumoto M; Miyazaki K
Br J Cancer; 2008 Dec; 99(12):2020-8. PubMed ID: 19018267
[TBL] [Abstract][Full Text] [Related]
32. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
33.
Chui MH; Kjaer SK; Frederiksen K; Hannibal CG; Wang TL; Vang R; Shih IM
Oncotarget; 2019 Dec; 10(64):6870-6878. PubMed ID: 31839880
[TBL] [Abstract][Full Text] [Related]
34. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
Sundov D; Caric A; Mrklic I; Gugic D; Capkun V; Hofman ID; Mise BP; Tomic S
Diagn Pathol; 2013 Feb; 8():21. PubMed ID: 23388101
[TBL] [Abstract][Full Text] [Related]
35. Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Nam JH; Kim YT
Yonsei Med J; 2009 Apr; 50(2):266-72. PubMed ID: 19430562
[TBL] [Abstract][Full Text] [Related]
36. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.
Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M
Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges.
Shih IeM; Kurman RJ
Clin Cancer Res; 2005 Oct; 11(20):7273-9. PubMed ID: 16243797
[TBL] [Abstract][Full Text] [Related]
38. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
[TBL] [Abstract][Full Text] [Related]
39. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors.
Sieben NL; Oosting J; Flanagan AM; Prat J; Roemen GM; Kolkman-Uljee SM; van Eijk R; Cornelisse CJ; Fleuren GJ; van Engeland M
J Clin Oncol; 2005 Oct; 23(29):7257-64. PubMed ID: 16087957
[TBL] [Abstract][Full Text] [Related]
40. Interobserver Reproducibility in Assessing Eosinophilic Cells in Ovarian Serous Borderline Tumors to Predict BRAF Mutational Status.
Chui MH; Murali R; Soslow RA; Matrai C; Xing D; Vang R
Int J Gynecol Pathol; 2023 Sep; 42(5):472-481. PubMed ID: 36867514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]